Avid Bioservices (NASDAQ:CDMO) issued its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.09), Bloomberg Earnings reports. Avid Bioservices had a negative return on equity of 52.55% and a negative net margin of 39.23%.
Avid Bioservices (NASDAQ:CDMO) traded up $0.11 during trading on Monday, hitting $2.44. The stock had a trading volume of 680,873 shares, compared to its average volume of 353,479. The stock has a market cap of $110.32, a P/E ratio of -3.49 and a beta of 2.43. Avid Bioservices has a 52 week low of $2.24 and a 52 week high of $5.78.
The firm also recently declared a dividend, which will be paid on Monday, April 2nd. Shareholders of record on Monday, March 19th will be paid a $0.6563 dividend. The ex-dividend date of this dividend is Friday, March 16th.
A number of analysts have issued reports on CDMO shares. Noble Financial reissued a “buy” rating on shares of Avid Bioservices in a research note on Tuesday, December 12th. Zacks Investment Research raised Avid Bioservices from a “sell” rating to a “hold” rating in a research note on Tuesday, February 27th. Finally, ValuEngine lowered Avid Bioservices from a “hold” rating to a “sell” rating in a research note on Friday, December 1st.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/03/12/avid-bioservices-cdmo-issues-earnings-results.html.
Avid Bioservices Company Profile
Avid Bioservices, Inc, formerly Peregrine Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. The Company delivers pharmaceutical products through its contract manufacturing business and through licensing its development-stage immunotherapy products.
Receive News & Ratings for Avid Bioservices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avid Bioservices and related companies with MarketBeat.com's FREE daily email newsletter.